Aakash Desai: What Does the FDA Decision Mean for Ivonescimab in EGFR-Mutant NSCLC?
Aakash Desai/LinkedIn

Aakash Desai: What Does the FDA Decision Mean for Ivonescimab in EGFR-Mutant NSCLC?

Aakash Desai, Associate Professor at UAB O’Neal Cancer Center, shared on LinkedIn:

“The FDA issued a complete response letter for ivonescimab (PD-1 × VEGF bispecific) + platinum chemotherapy in EGFR-mutant NSCLC after EGFR TKI therapy. Per Summit the FDA said a PFS benefit without a statistically significant OS improvement does not support a positive benefit-risk profile.

HARMONi (Lancet Oncology, n=438, dual primary endpoints PFS and OS):

  • Median PFS 6.8 vs 4.4 months, HR 0.52
  • Median OS 16.8 vs 14.0 months, HR 0.79 (95% CI 0.62–1.01), not significant
  • Serious treatment-related AEs 28% vs 15%

Summit cites a post hoc OS HR of 0.76 with longer follow-up.

Two things to weight for this decision:

  • PFS has supported approvals elsewhere, so consistency matters. In this same post-TKI setting, the FDA approved amivantamab + chemo (MARIPOSA-2) on PFS, HR 0.48, with OS not significant at that analysis (HR 0.73). One difference: OS was a key secondary endpoint there and a co-primary endpoint in HARMONi.
  • The question now is added value over today’s EGFR care, not PFS over chemo alone. FLAURA2 (OS HR 0.77) and MARIPOSA (OS HR 0.75) have already moved survival in the first line.

Both points hold. I lean toward the value question. PFS can be enough when the gain is large and patients feel it. Here OS was a stated primary goal and missed, and serious toxicity was higher. Before I call this a new option after osimertinib, I want to see OS or quality-of-life gains.

What OS or quality-of-life bar should the next post-osimertinib trials be designed to meet?

SummitTherapeutics”

Read The Full Article.

Title: Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial

Authors: Xiuning Le, Antonio Passaro, Yuanyuan Zhao, Yan Huang, Janessa Laskin, Delvys Rodriguez-Abreu, Antonio Calles, Lyudmila Bazhenova, Giuseppe Lo Russo, Natasha B Leighl, Federico Cappuzzo, Nicolas Girard, Sanjay Popat, Wenfeng Fang, Yongzhong Luo, Wenting Li, Zhiyong He, Hui Zhao, Mingjun Li, Qibin Song, Hongyun Zhao, Haidar El Darsa, Isabelle Monnet, Manuel Cobo Dols, Rosario García Campelo, Robert Jotte, David Berz, Alexander Spira, Maurice Pérol, Misako Nagasaka, Howard West, Lori Styles, Jianling Li, Fong Clow, Jonathan Goldman, Li Zhang.

You can also read: FDA Declines Ivonescimab Plus Chemotherapy Approval in EGFR-Mutated NSCLC Following HARMONi Results

Aakash Desai: What Does the FDA Decision Mean for Ivonescimab in EGFR-Mutant NSCLC?